Skip to main content
SpringerLink
Log in

Genetic factors in vincristine-related peripheral neuropathy

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. In the COG trial, one group of patients had been randomised to receive a vincristine dose of 2.5 mg/m2 (maximum dose of 2.5mg; group B) but treatment in this group was permanently suspended by COG in 2010 due to a high incidence of peripheral neuropathy (most prominently in patients aged ≥13 years).

References

  1. Diouf B, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA: the Journal of the American Medical Association 313: 815-23, No. 8, 24 Feb 2015.

    Article  CAS  Google Scholar 

  2. McLeod HL. Precision medicine to improve the risk and benefit of cancer care: genetic factors in vincristine-related neuropathy. JAMA: the Journal of the American Medical Association 313: 803-4, No. 8, 24 Feb 2015.

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Genetic factors in vincristine-related peripheral neuropathy. Reactions Weekly 1542, 11 (2015). https://doi.org/10.1007/s40278-015-8419-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-015-8419-5

Search

Navigation